Mijin Jung

Title: Mijin Jung - Innovator in Antibody Stability

Introduction

Mijin Jung is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies with enhanced stability. His work is crucial for advancing treatments for autoimmune diseases.

Latest Patents

Mijin Jung holds a patent for an "Anti-FcRn antibody or antigen binding fragment thereof with improved stability." This patent describes an innovative anti-FcRn antibody that binds non-competitively with IgG, leading to improved stability. The invention reduces the production rate of aggregates while maintaining the biological activity necessary for significantly decreasing pathogenic autoantibodies in the blood. This advancement may enhance the efficiency of treatments for autoimmune diseases.

Career Highlights

Throughout his career, Mijin Jung has worked with prominent companies in the biotechnology sector. He has been associated with Hanall Biopharma Co., Ltd. and Immunovant Sciences GmbH. His expertise in antibody development has positioned him as a key player in the industry.

Collaborations

Mijin Jung has collaborated with several professionals in his field, including William Louis Macias and Su Liang. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Mijin Jung's work in developing stable antibodies represents a significant step forward in the treatment of autoimmune diseases. His innovative approach and collaborations continue to influence the biotechnology landscape.